Alzinova AB (publ) (ALZ.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 0.3865 (-7.20%) as of
Key statistics
- Market cap
- 122.16M
- Forward P/E
- -0.64
- EPS (TTM)
- -0.2100
- Dividend yield
- 0.00%
- 52-week range
- 0.3680 – 2.0700
- Beta
- 1.24
- Revenue (TTM)
- 149k
- Profit margin
- 0.00%
- Analyst target
- SEK 1.20
- Volume
- 4.13M
About Alzinova AB (publ)
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. It has a research collaboration with Amsterdam University Medical Center to develop a blood based test that measures naturally occurring antibodies against toxic amyloid ß oligomers. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Mölndal, Sweden
- Employees
- 7
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.